Alkermes (ALKS) CMO exercises options and sells 5,000 shares in plan trade

Rhea-AI Filing Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an options exercise and share sale. On 01/08/2026 he exercised an employee stock option for 5,000 ordinary shares at an exercise price of $19.34 per share and then sold 5,000 ordinary shares at a weighted average price of $30.001 per share, with individual sale prices ranging from $30.00 to $30.01.

Both the option exercise and the sale were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025, and the options exercised were fully vested in accordance with their terms. After these transactions, he directly owned 61,740 ordinary shares and 31,356 employee stock options.

Insider Trade Summary

Net Seller: 5,000 shares ($150,005)

Net Sell 3 txns

Insider Hopkinson Craig C.

Role EVP R&D, Chief Medical Officer

Sold 5,000 shs ($150K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	5,000	$0.00	--
Exercise	Ordinary Shares	5,000	$19.34	$97K
Sale	Ordinary Shares	5,000	$30.001	$150K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 31,356 shares (Direct); Ordinary Shares — 66,740 shares (Direct)

Footnotes (1)

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. These options are fully vested in accordance with their terms.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last) (First) (Middle)

900 WINTER ST.

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP R&D, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/08/2026		M(1)		5,000	A	$19.34	66,740	D
Ordinary Shares	01/08/2026		S(2)		5,000	D	$30.001(3)	61,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$19.34	01/08/2026		M(1)			5,000	(4)	02/22/2031	Ordinary Shares	5,000	$0	31,356	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Alkermes (ALKS) report for Craig C. Hopkinson?

On 01/08/2026, EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised an employee stock option for 5,000 ordinary shares at $19.34 per share and sold 5,000 ordinary shares at a weighted average price of $30.001 per share.

How many Alkermes (ALKS) shares does Craig C. Hopkinson hold after this Form 4?

Following the reported transactions, Craig C. Hopkinson directly owned 61,740 ordinary shares of Alkermes plc and held 31,356 employee stock options.

What trading plan governed Craig C. Hopkinson’s Alkermes (ALKS) transactions?

Both the option exercise and the sale were effected under a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025, as disclosed in the footnotes.

What prices were involved in Craig C. Hopkinson’s Alkermes (ALKS) share sale?

The Form 4 reports a weighted average sale price of $30.001 per share, with the 5,000 ordinary shares sold in multiple transactions at prices ranging from $30.00 to $30.01.

What are the key terms of the exercised Alkermes (ALKS) stock options?

The exercised security was an Employee Stock Option (Right to Buy) for 5,000 ordinary shares with an exercise price of $19.34 per share and an expiration date of 02/22/2031. The footnotes state these options were fully vested.

Is Craig C. Hopkinson an officer of Alkermes (ALKS)?

Yes. The Form 4 identifies Craig C. Hopkinson as an officer of Alkermes plc with the title EVP R&D, Chief Medical Officer.